Combined beneficial effect of rasagiline on motor function and depression in de novo PD

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 121-124

  Korchounov, Alexei ^a   Winter, Yaroslav ^b   Rössy, Wolfgang ^c  

^a Parkinson Department   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Clinic for Neurology Bad Schönborn   (Germany)

Author keywords

aminoindan; depression; Parkinson disease; rasagiline; treatment

Indexed keywords

RASAGILINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GUILT; HAMILTON SCALE; HUMAN; HYPOCHONDRIASIS; INSOMNIA; MALE; MOOD; MOTOR PERFORMANCE; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84861527199     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31823b1da8     Document Type: Article

References (16)

1. Aarsland D, BrLnnick K, Alves G. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:928Y930.
2. Starkstein SE. Neuropsychiatric disorders in early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:830.
3. Starkstein SE, Mayberg HS, Leiguarda R. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377Y382.
4. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in Parkinson's disease. N Engl J Med 1993;328:176Y183.
5. Macleod AD, Counsell CE, Ives N, et al. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005;3:CD004898.
6. Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:547.
7. Robinson DS, Gilmor ML, Yang Y. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull 2007;40:15Y28.
8. Food and Drug Administration press release, February 28, 2006.
9. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 2002;59:1937Y1943.
10. Daniel SE, Lees AJ. Parkinson Disease Society Brain Bank: overview and research. J Neural Transm 1993;39:165Y172.
11. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278Y296.
12. Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000;15:644Y649.
13. Brotchie J, Johnston T, Visanji N. 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease. Parkinsonism Relat Disord 2007;13(suppl 2):S102.
14. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314Y1322.
15. Thébault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004;24:1295Y1305.
16. Olanow CW, Rascol A, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268Y1278.